Patent Evaluation Central & Peripheral Nervous Systems: Benzimidazole and imidazopyridine derivatives as dopamine D₃ receptor antagonists for the treatment of psychosis

Abstract

A series of benzimidazole and imidazopyridine derivatives are claimed in this patent to have utility in the treatment of neuropsychiatric conditions, especially schizophrenia and related psychoses. This claim is based on nanomolar affinities of these compounds for the dopamine D₃ receptor, and the relative selectivity of these agents for the D₃ vs. the D₂ receptor.